---
title: "Microport Neuro shareholders will transfer shares from Construction Asia to GUOYUAN SECURITIES brokerage, with a transfer value of HKD 856 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262792675.md"
description: "According to the latest data from the Hong Kong Stock Exchange, on October 24th, shareholders of MICROPORT NEURO transferred their shares from Construction Asia to GUOYUAN SECURITIES brokerage, with a transfer market value of HKD 856 million, accounting for 12.94%. MICROPORT NEURO announced its mid-term results for 2025, with revenue of approximately HKD 383 million, a year-on-year decrease of 6.2%; the profit attributable to equity shareholders was HKD 92.923 million, a year-on-year decrease of 35.25%; earnings per share were HKD 0.16. As of the end of the reporting period, the group had a total of 8 products that achieved overseas expansion, with commercialization in 34 overseas countries or regions, covering 9 countries that rank in the top ten globally for neuro-interventional surgery volume"
datetime: "2025-10-27T00:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262792675.md)
  - [en](https://longbridge.com/en/news/262792675.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262792675.md)
generator: "portal-rs"
---

# Microport Neuro shareholders will transfer shares from Construction Asia to GUOYUAN SECURITIES brokerage, with a transfer value of HKD 856 million

According to the latest information from the Hong Kong Stock Exchange, on October 24th, MicroPort Neuro (02172) shareholders transferred their stocks from Construction Asia to Guoyuan Securities brokerage, with a transfer market value of HKD 856 million, accounting for 12.94%.

MicroPort Neuro announced its interim results for 2025, with revenue of approximately HKD 383 million, a year-on-year decrease of 6.2%; the profit attributable to equity shareholders was HKD 92.923 million, a year-on-year decrease of 35.25%; earnings per share were HKD 0.16. As of the end of the reporting period, the group had 8 products that achieved overseas expansion, with commercialization in 34 overseas countries or regions, covering 9 countries that rank in the top ten globally for neuro-interventional procedures

### Related Stocks

- [02172.HK](https://longbridge.com/en/quote/02172.HK.md)
- [000728.CN](https://longbridge.com/en/quote/000728.CN.md)

## Related News & Research

- [Asia Naphtha/Gasoline-Naphtha prices rise mirroring crude gains](https://longbridge.com/en/news/298443702.md)
- [Short Interest in LeGrand SA (OTCMKTS:LGRDY) Rises By 987.4%](https://longbridge.com/en/news/298664688.md)
- [Bonjour Holdings Requests Trading Halt Pending Inside Information Announcement](https://longbridge.com/en/news/298681082.md)
- [REG - Trium Capital LLP Eleco PLC - Form 8.3 - ELECO PLC](https://longbridge.com/en/news/298744146.md)
- [Trading in CLOUDBREAK-B Halted This Morning at SFC's Direction](https://longbridge.com/en/news/298521481.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**